Skip to main content
oAv Menu
Home
Patient Care Center
Clinical Trials
Providers
Therapeutics
People
Places
Community Center
Community Stories
Social Media
Community Content
Financial Assistance
News
Community Events
Clinical Trials and Research
Business
News People
Happenings
Spotlight
Fundraising Events
Trusted Resources
Education
Videos & Visuals
Event Calendar
Login
Search
Home
Providers
Therapeutics
Alnylam® Pharmaceuticals
Alnylam® Pharmaceuticals
Alnylam Announces FDA Approval of AMVUTTRA™ (Vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Read more
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
Read more
Alnylam Reports Positive Topline 18-Month Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR Amyloidosis With Polyneuropathy
Read more
Alnylam Reports Positive Topline Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR Amyloidosis With Polyneuropathy
Read more
Alnylam Pharmaceuticals - Linkedin
Read more
FDA Approves Alnylam’s Onpattro for Polyneuropathy of hATTR Amyloidosis
Read more
FDA Approves Patisiran Infusion for Hereditary Transthyretin-Mediated Amyloidosis
Read more
Pagination
« First
First page
‹‹
Previous page
1
2
